Group 1 - The Chinese medicine index (930641) has seen a strong increase of 2.61%, with notable gains in constituent stocks such as Longshen Rongfa (300534) up 20.05% and Shanghai Kaibao (300039) up 7.44% [1] - The Chinese medicine ETF (560080) has risen by 2.70%, with a latest price of 1.06 yuan and a trading volume reaching 100 million yuan, indicating a turnover rate of 4.58% [1] - Over the past two weeks, the Chinese medicine ETF has experienced a significant growth in scale, increasing by 61.09 million yuan and adding 81.5 million shares, ranking in the top quarter among comparable funds [1] Group 2 - On March 20, the State Council issued an opinion aimed at enhancing the quality of traditional Chinese medicine (TCM) and promoting high-quality development in the TCM industry, focusing on quality improvement, technological innovation, and systemic reforms [2] - Ping An Securities notes that the opinion covers various aspects of the TCM industry, including resource development, clinical application, and innovation in TCM, suggesting that improved price regulation and brand strategies will enhance the profitability of TCM companies [3] - The opinion also emphasizes the need for optimized procurement policies for TCM, which may reduce price risks for high-quality TCM products, and encourages the development of innovative TCM drugs with significant clinical efficacy [3]

Core Insights - The report highlights China Resources Sanjiu's commitment to sustainable development and ESG practices under its "14th Five-Year Plan" strategy, focusing on green manufacturing and social responsibility while identifying areas for improvement in supply chain ESG management and biodiversity protection [1] Group 1: ESG Highlights - The company has established near-zero carbon park trials, with distributed photovoltaic annual power generation reaching 10.7841 million kWh and a green electricity self-use rate of 92.9% [2] - Smart manufacturing initiatives have led to a 20% increase in production efficiency and a 12% reduction in energy consumption per unit of output at the Guanlan base [2] - The number of national-level green factories has increased to 7, with greenhouse gas emission intensity reduced by 13.58% year-on-year, exceeding the "14th Five-Year Plan" targets [2] - The board of directors shows diversity, with female directors making up 18.18%, and 24 board meetings held throughout the year, with compliance training covering 100% of employees [2] - Supply chain risk management has been strengthened, with 742 suppliers completing ESG audits and anti-corruption training reaching 53,000 participants, with no major corruption incidents reported [2] - Employee training investment totaled 10.432 million yuan, with an average of 30.32 hours of training per employee [2] - The innovative "Three Uncle Health Steward" initiative has conducted over 96 community health public welfare events, benefiting tens of thousands of people [2] Group 2: ESG Shortcomings - Only 43% of subsidiaries have obtained ISO 14001 certification, and the ESG training coverage for suppliers is below 50%, indicating weak environmental compliance capabilities among some small and medium-sized suppliers [3] - The report mentions genetic resource protection but lacks established ecological impact assessment indicators for medicinal herb cultivation [3] - Overall, the company's ESG practices reflect the foresight of a leading player in the traditional Chinese medicine industry, balancing commercial value with social benefits, but still requires breakthroughs in supply chain empowerment and quantitative biodiversity management [3]

涉及总金额6 0 1 . 4 4亿元人民币。 作者 | 私募通 报道 | 决策投资圈 （ID： PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购共167起事件，涉及总 金额601.44亿人民币。从交易金额来看，本周金额较大事件是：2025年3月27日，华润三九医药股份有限公 司成功受让天士力生物医药产业集团有限公司、天津和悦科技发展合伙企业（有限合伙）、天津康顺科技发 展合伙企业（有限合伙）、天津顺祺科技发展合伙企业（有限合伙）、天津善臻科技发展合伙企业（有限合 伙）等持有的天士力医药集团股份有限公司的28. 0%的股权，作价59.90亿人民币。从交易事件地域分布看， 目前主要分布在广东省、江苏省和浙江省，占比为广东省15.6%，江苏省13.8%，浙江省12 .6%。 更多信息请登录：htt ps://ma x.pe da t a . c n/ 本周新登记股权投资基金管理人共计0家，取消备案登记12家，全年截至目前累计股权投资基金管理人数量 为17家。本周新增备案基金数量为85只，规模总计41 8. 88亿元，本周备案基金募资最多的为南京江宁智慧股 权投 ...

Core Viewpoint - The launch of 999 Yiqi Qingfei Granules by China Resources Sanjiu marks a significant advancement in the treatment of respiratory infection recovery symptoms, filling a market gap for rehabilitation medications [1][2]. Group 1: Product Launch and Significance - China Resources Sanjiu officially released its first traditional Chinese medicine class 3.2 new drug, 999 Yiqi Qingfei Granules, at the First Traditional Chinese Medicine Industry Interconnectivity Conference [1]. - The drug is developed in collaboration with academician Zhang Boli and is the first to be approved by the National Medical Products Administration specifically for treating symptoms during the recovery phase of respiratory infections [1][2]. - The launch signifies an expansion of China Resources Sanjiu's product offerings in the respiratory category, aiming to address the rehabilitation issues often overlooked in respiratory infections [1][2]. Group 2: Development and Composition - The formulation of 999 Yiqi Qingfei Granules is based on classic prescriptions such as Shengmai San and Pingwei San, adjusted according to clinical rehabilitation experiences [2]. - The granules focus on enhancing energy and nourishing yin, improving symptoms like fatigue, shortness of breath, and dry cough with little phlegm during the recovery phase of respiratory infections [2]. Group 3: Strategic Vision - The company aims to leverage traditional Chinese medicine values through innovative research, providing safe and effective treatment options for consumers suffering from prolonged cold symptoms [2]. - The product is part of a broader "1+N" brand strategy that encompasses full-cycle management of common household diseases, indicating a comprehensive approach to health care [2]. - 999 Yiqi Qingfei Granules is positioned as a key product in the company's respiratory category, highlighting its strategic importance for future growth [2].

Group 1 - CIMC reported a net profit of RMB 29.72 billion for 2024, a year-on-year increase of 605.60% [1] - CIMC's revenue reached RMB 1,776.64 billion, up 39.01% from the previous year [1] - The container manufacturing segment generated revenue of RMB 622.05 billion, a 105.89% increase year-on-year [1] Group 2 - CIMC Vehicles reported revenue of RMB 209.98 billion, a decrease of 16.30% year-on-year [2] - Net profit for CIMC Vehicles fell to RMB 10.81 billion, down 55.83% compared to the previous year [2] - The decline in net profit was attributed to normalization of North American business and non-recurring gains from a previous equity disposal [2] Group 3 - SMIC's revenue for 2024 was RMB 57,795.6 million, an increase of 27.7% year-on-year [3] - The net profit for SMIC decreased by 23.3% to RMB 3,698.7 million [3] - The increase in revenue was driven by a rise in wafer sales volume, which increased by 36.7% [3] Group 4 - Haier Smart Home achieved a net profit of RMB 187.41 billion, a year-on-year increase of 12.92% [4] - The company reported revenue of RMB 2,859.81 billion, up 4.29% from the previous year [4] - The gross margin for Haier Smart Home was 27.8%, an increase of 0.3 percentage points from 2023 [4] Group 5 - CNOOC reported a net profit of RMB 137.94 billion for 2024, an increase of 11.4% year-on-year [6] - The company's revenue was RMB 420.51 billion, a slight increase of 0.9% from the previous year [6] - CNOOC's oil and gas production reached 199 million barrels of oil equivalent per day [6] Group 6 - CNOOC's oil liquid sales volume increased by 9.4% to 562.9 million barrels [7] - The average realized oil price was USD 76.75 per barrel, a decrease of approximately 1.6% [7] - The company achieved a reserve replacement rate of 167% with 11 new discoveries [7] Group 7 - China Merchants Securities reported a net profit of RMB 103.86 billion, an increase of 18.51% year-on-year [8] - The company achieved revenue of RMB 208.91 billion for the year [8] - Wealth management and institutional business contributed RMB 102.33 billion to the revenue [8] Group 8 - China Merchants Energy reported a net profit of RMB 51.07 billion for 2024 [9] - The company's revenue was RMB 257.99 billion, with a slight decrease of 0.32% [9] - The revenue decline was influenced by fluctuations in the oil tanker market [9] Group 9 - Industrial Bank achieved a net profit of RMB 772.05 billion, a year-on-year increase of 0.12% [11] - The bank's revenue was RMB 2,122.26 billion, up 0.66% from the previous year [11] - The non-performing loan ratio was 1.07%, indicating stable asset quality [11] Group 10 - Weichai Power reported a net profit of RMB 114.03 billion, a year-on-year increase of 26.51% [12] - The company's revenue reached RMB 2,156.9 billion, up 0.81% [12] - The sales of various engines totaled 734,000 units, with a 5% increase in exports [13] Group 11 - Lens Technology achieved a net profit of RMB 36.24 billion, a year-on-year increase of 19.94% [14] - The company reported revenue of RMB 698.97 billion, up 28.27% [14] - The smartphone and computer segments contributed significantly to revenue growth [14] Group 12 - Shandong Gold reported a net profit of RMB 29.52 billion, a year-on-year increase of 26.80% [15] - The company's revenue was RMB 825.18 billion, up 39.21% [15] Group 13 - Huadian International achieved a net profit of RMB 57.03 billion, a year-on-year increase of 26.11% [16] - The company's revenue was RMB 1,129.94 billion, a decrease of 3.57% [16] Group 14 - Postal Savings Bank reported a revenue of RMB 348.77 billion, a year-on-year increase of 1.83% [16] - The bank's net interest income was RMB 286.12 billion, up 1.53% [16] Group 15 - Joyoung reported a net profit of RMB 1.22 billion, a year-on-year decrease of 68.55% [17] - The company's revenue was RMB 8.85 billion, down 7.94% [17] Group 16 - Shanghai Pharmaceuticals achieved a net profit of RMB 45.53 billion, a year-on-year increase of 20.82% [18] - The company's revenue was RMB 2,752.51 billion, up 5.75% [18] Group 17 - CITIC Securities reported a net profit of RMB 72.23 billion, a year-on-year increase of 2.68% [19] - The company's revenue was RMB 211.29 billion, down 9.1% [19] Group 18 - Three squirrels plan to issue H-shares and apply for listing on the Hong Kong Stock Exchange [21] - The company aims to enhance global brand recognition and expand overseas financing capabilities [21] Group 19 - CIMC announced the termination of the spin-off of its subsidiary CIMC Tianda for listing on the Shenzhen Stock Exchange [22] - The decision was made for comprehensive considerations regarding business development and capital operation planning [22] Group 20 - CNOOC's subsidiary CIMC Tianda withdrew its IPO application [23] - The expected fundraising amount was RMB 1.41941 billion [23]

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has completed the acquisition of 418,306,002 shares of Tianjin Tasly Pharmaceutical Group Co., Ltd., representing 28% of its total issued shares, thereby becoming its controlling shareholder [2][3][4]. Group 1: Transaction Details - The acquisition was executed through cash payment to Tasly Group and its affiliates, with the shares transferred to China Resources Sanjiu [2]. - The shares acquired include 351,619,489 shares from Tasly Group and smaller amounts from its affiliates [2]. - Following the transaction, the controlling shareholder of Tasly will change from Tasly Group to China Resources Sanjiu, with the actual controller being China Resources Limited [2]. Group 2: Payment Structure - The payment for the share transfer is structured in three phases: 1. 35% of the transfer price to be paid within 10 working days of the agreement's effectiveness [7]. 2. 55% to be paid within 10 working days after the shares are registered under China Resources Sanjiu's name [7]. 3. The remaining 10% to be paid within 10 working days after a 6-month period post-registration [7]. - As of the announcement date, the first payment has already been made [7]. Group 3: Post-Transaction Matters - Following the completion of the share transfer, there are still outstanding payments and commitments that need to be fulfilled according to the share transfer agreement [8]. - The company is required to continue fulfilling its information disclosure obligations as per relevant laws and regulations [8]. Group 4: Verification Opinions - The independent financial advisor, Huatai United Securities, confirmed that the transaction complies with relevant laws and that the share transfer procedures are legal and effective [9]. - The legal advisor, Shanghai Jintiancheng Law Firm, also affirmed that the transaction followed the necessary legal procedures and that there are no significant discrepancies in the information disclosed [10][11].

华泰联合证券有限责任公司 关于华润三九医药股份有限公司 重大资产购买实施情况报告书 华泰联合证券有限责任公司（以下简称"华泰联合"、"本独立财务顾问"）接 受华润三九医药股份有限公司（以下简称"华润三九"、"上市公司"或"公司"） 委托，担任本次重大资产购买（以下简称"本次交易"）的独立财务顾问，就该事项 向上市公司全体股东提供独立意见，并制作本核查意见。 本独立财务顾问核查意见是依据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司重大资产重组管理办法》《上市公司并购重组财务顾问业务管理办 法》《公开发行证券的公司信息披露内容与格式准则第 26 号——上市公司重大资产重 组》等法律法规及文件的规定和要求，以及证券行业公认的业务标准、道德规范，经 过审慎调查，本着诚实信用和勤勉尽责的态度，就本次交易认真履行尽职调查义务， 对上市公司相关文件进行审慎核查后出具的，旨在就本次交易行为做出独立、客观和 公正的评价，以供上市公司全体股东及有关各方参考。 本独立财务顾问核查意见所依据的文件和材料由本次交易各方提供，提供方对所 提供文件及资料的真实性、准确性和完整性负责，并保证该等信息不存在虚假记载、 误导性陈 ...

地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司重大资产购买 实施情况 之法律意见书 上海市锦天城（深圳）律师事务所 法律意见书 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 日 录 | 一、 本次交易方案概述 | | --- | | 二、 本次交易的批准与授权 | | 三、 本次交易的实施情况 … | | .. 四、 信息披露 | | 五、 相关协议及承诺的履行情况 | | 六、 本次交易的后续事项 | | 七、结论意见 . | 2 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司重大资产购买 实施情况 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"上市公司"或"华润三九"）的委托，并根据华润三 九与本所签订的《专项法律服务合同》，作为华润三九以支付现金的方式收购天 士力医药集团股份有限公司（以下简称"天士力"、"标的公司"）418,306,002 股股份（占天 ...

本次交易有关监管部门对本次交易事项所作的任何决定或意见，均不代表其对本 公司股票的价值或投资者收益的实质性判断或保证。任何与之相反的声明均属虚假不 实陈述。 证券代码：000999 证券简称：华润三九 上市地：深圳证券交易所 华润三九医药股份有限公司 重大资产购买 实施情况报告书 独立财务顾问 签署日期：二〇二五年三月 上市公司声明 本公司及董事会全体成员保证本报告书内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 根据《证券法》等相关法律、法规的规定，本次交易完成后，本公司经营与收益 的变化，由本公司自行负责，由此变化引致的投资风险，由投资者自行负责。投资者 若对本报告书存在任何疑问，应咨询自己的股票经纪人、律师、会计师或其他专业顾 问。 本公司提醒投资者注意：本报告书的目的仅为向公众提供有关本次交易的实施情 况，投资者如欲了解更多信息，请仔细阅读本公司《华润三九医药股份有限公司重大 资产购买报告书（草案）（修订稿）》全文。 1 | 目录 | | --- | | 上市公司声明 | 1 | | --- | --- | | 释义 | 3 | | 第一节 | 本次交易概 ...

股票代码：000999 股票简称：华润三九 编号：2025—032 华润三九医药股份有限公司 关于重大资产购买之标的资产过户完成暨取得其控制权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"华润三九"或"公司"）以支付现 金的方式向天士力生物医药产业集团有限公司（以下简称"天士力集团"）及其 一致行动人天津和悦科技发展合伙企业（有限合伙）（以下简称"天津和悦"）、 天津康顺科技发展合伙企业（有限合伙）（以下简称"天津康顺"）、天津顺祺科 技发展合伙企业（有限合伙）（以下简称"天津顺祺"）、天津善臻科技发展合伙 企业（有限合伙）（以下简称"天津善臻"）、天津通明科技发展合伙企业（有限 合伙）（以下简称"天津通明"）、天津鸿勋科技发展合伙企业（有限合伙）（以下 简称"天津鸿勋"）合计购买其所持有的天士力医药集团股份有限公司（以下简 称"天士力"）418,306,002 股股份（占天士力已发行股份总数的 28%）（以下简 称"本次交易"），具体包括天士力集团持有的天士力 351,619,489 股股份，天津 和悦持有的天士 ...